Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer’s Disease. September 30, 2009
Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I Alzheimer’s Disease Clinical Trials September 21, 2009
Anti-amnesic and neuroprotective activities of ANAVEX2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligand, in pharmacological and pathological models of amnesia. July 11, 2009
ANAVEX Appoints Dr. Hervé de Kegrohen as CEO to Lead Company Through Clinical Trials and Future Growth June 16, 2009
Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board February 10, 2009
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology December 17, 2008
Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on Alzheimer’s Disease 2008 July 30, 2008
